# US 2010/0168250 A1 · Use of cyclohexanehexol derivatives in the treatment of ocular disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168250 A1
- Document ID: US20100168250A1
- Status: Published application
- Kind: A1
- Application number: 12/594,951
- Filed: 2008-04-11
- Published: 2010-07-01
- Earliest claimed: 2007-04-12
- Inventors: Antonio Cruz
- Web page: https://patentgrep.com/patent/US20100168250A1

## CPC

- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods of treating ocular diseases in a subject by administering to the subject a therapeutically effective amount of one or more cyclohexanehexol derivatives, or salts thereof, or a medicament comprising a cyclohexanehexol derivative and a pharmaceutically acceptable carrier. More specifically, the invention provides a medicament comprising at least one cyclohexanehexol derivative of formula (III) or (IV) useful in preventing or treating ocular diseases, by modulating the folding, oligomerization or aggregation of amyloid β in ocular cells. Methods of administration of these medicaments include systemic, transpleural, oral, intravenously, intraarterial, intramuscular, topical, via inhalation, transdermal, subcutaneous, intraperitoneal, gastrointestinal, and directly to the eye or tissues surrounding the eyes.

## Claims

### Claim 1

A medicament for treating an ocular disease comprising a therapeutically effective amount of a cyclohexanehexol compound of the formula III or IV:
wherein X is a cyclohexane ring, wherein R1, R2, R3, R4, R5, and R6 are hydroxyl or at least one of R1, R2, R3, R4, R5, and R6 is independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6alkoxy, C2-C6 alkenyloxy, C3-C10 cycloalkyl, C4-C10cycloalkenyl, C3-C10cycloalkoxy, C6-C10aryl, C6-C10aryloxy, C6-C10aryl-C1-C3alkoxy, C6-C10aroyl, C6-C10heteroaryl, C3-C10heterocyclic, C1-C6acyl, C1-C6acyloxy, —NH2, —NHR7, —NR7R8, ═NR7, —S(O)2R7, —SH, —SO3H, nitro, cyano, halo, haloalkyl, haloalkoxy, hydroxy alkyl, —Si(R7)3, —OSi(R7)3, —CO2H, —CO2R7, oxo, —PO3H, —NHC(O)R7, —C(O)NH2, —C(O)NHR7, —C(O)NR7R8, —NHS(O)2R7, —S(O)2NH2, —S(O)2NHR7, and —S(O)2NR7R8 wherein R7 and R8 are independently selected from C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C10cycloalkyl, C4-C10cycloalkenyl, C6-C10aryl, C6-C10 aryl C1-C3alkyl, C6-C10 heteroaryl and C3-C10heterocyclic, and at least one of the remainder of R1, R2, R3, R4, R5, or R6 is hydroxyl; or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A medicament according to claim 1 wherein the cyclohexanehexol compound is a compound of the formula III or IV wherein R2 is hydroxyl; and R1, R3, R4, R5, and R6 are independently selected from C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1C6alkoxy, C2-C6alkenyloxy, C3-C10cycloalkyl, C4-C10cycloalkenyl, C3-C10cycloalkoxy, C6-C10aryl, C6-C10aryloxy, C6-C10aryl-C1-C3alkoxy, C6-C10aroyl, C6-C10heteroaryl, C3-C10 heterocyclic, C1-C6acyl, C1-C6acyloxy, hydroxyl, —NH2, —NHR7, —NR7R8—, ═NR7, —S(O)2R7, —SH, —SO3H, nitro, cyano, halo, haloalkyl, haloalkoxy, hydroxyalkyl, —Si(R7)3, —OSi(R7)3, —CO2H, —CO2R7, oxo, —PO3H, —NHC(O)R7, —C(O)NH2, —C(O)NHR7, —C(O)NR7R8, —NHS(O)2R7, —S(O)2NH2, —S(O)2NHR7, and —S(O)2NR7R8 wherein R7 and R8 are independently selected from C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C10 cycloalkyl, C4-C10cycloalkenyl, C6-C10aryl, C6-C10aryl C1-C3alkyl, C6-C10heteroaryl and C3-C10heterocyclic; provided that R1, R2, R3, R4, R5, and R6 are not all hydroxyl.

### Claim 3 (depends on 1)

A medicament according to claim 1 wherein the cyclohexanehexol compound is a compound of the formula III or IV wherein one of R1, R3, R4, R5, and R6 is C1-C6alkyl, C1-C6alkoxy, C1-C6acyl, halo, oxo, ═NR7, —NHC(O)R7, —C(O)NH2, —C(O)NHR7, —C(O)NR7R8, CO2R7, or —SO2R7, wherein R7 and R8 are independently selected from C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C10cycloalkyl, C4-C10cycloalkenyl, C6-C10aryl, C6-C10aryl C1-C3alkyl, C6-C10heteroaryl and C3-C10heterocyclic.

### Claim 4 (depends on 1)

A medicament according to claim 1 wherein the cyclohexanehexol compound is a compound of the formula III or IV wherein two of R1, R3, R4, R5, and R6 are C1-C6alkyl, C1-C6alkoxy, C1-C6acyl, halo, oxo, ═NR7, —NHC(O)R7, —C(O)NH2, —C(O)NHR7, —C(O)NR7R8, CO2R7, or —SO2R7, R7 and R8 are independently selected from C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C10cycloalkyl, C4-C10cycloalkenyl, C6-C10aryl, C6-C10aryl C1-C3alkyl, C6-C10heteroaryl and C3-C10heterocyclic; and no more than four of R1, R2, R3, R4, R5, and R6 are hydroxyl.

### Claim 5 (depends on 1)

A medicament according to claim 1 wherein the cyclohexanehexol compound is a compound of the formula III or IV wherein at least one, two, three or four of R1, R3, R4, R5, and/or R6 are hydroxyl and the other of R1, R3, R4, R5, and/or R6 are C1-C6 alkyl, C1-C6 alkoxy, or halo.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A medicament according to any one of claims 1 to 5 wherein the cyclohexanehexol compound is scyllo-inositol.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A medicament according to any one of claims 1 to 6 for use in the treatment of an ocular disease characterized by amyloid aggregate deposition.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

A medicament according to any one of claims 1 to 6 wherein the amount of cyclohexanehexol compound is effective to modulate assembly, folding, accumulation, rate of aggregation and/or clearance of amyloid aggregates.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6)

A medicament according to any one of claims 1 to 6 wherein the amount of cyclohexanehexol compound is effective to prevent, disrupt or inhibit assembly or reverse or reduce amyloid aggregation in ocular cells after the onset of symptoms of an ocular disease.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6)

A method for preventing or inhibiting assembly of, or reversing or reducing amyloid, and/or oligomers and/or aggregates comprising amyloid in ocular cells in a subject after the onset of symptoms of an ocular disease comprising administering a therapeutically effective amount of a medicament according to any one of claims 1 to 6.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6)

A method for disrupting or enhancing clearance or degradation of oligomers and/or aggregates comprising amyloid in ocular cells in a subject after the onset of symptoms of an ocular disease comprising administering a therapeutically effective amount of a medicament according to any one of claims 1 to 6.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6)

A method for improving ocular function and/or slowing degeneration of ocular cells in a subject after the onset of symptoms of an ocular disease comprising administering a therapeutically effective amount of a medicament according to any one of claims 1 to 6.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6)

A method for delaying the onset or progression of ocular impairment associated with an ocular disease in a subject comprising administering to the subject a therapeutically effective amount of a cyclohexanehexol compound, or a medicament according to any one of claims 1 to 6.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6)

A method for treating glaucoma in a subject comprising administering to the subject a therapeutically effective amount of a medicament according to any one of claims 1 to 6.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6)

A method for treating macular degeneration in a subject comprising administering a cyclohexanehexol compound as defined in any one of claims 1 to 6 and a pharmaceutically acceptable carrier, excipient, or vehicle which causes dissolution and/or disruption of pre-existing amyloid aggregates in macular cells.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6)

A method for treating a mammal in need of improved ocular function, wherein the mammal has no diagnosed disease, disorder, infirmity or ailment known to impair or otherwise diminish ocular function, comprising the step of administering to the mammal a therapeutically effective amount for improving ocular function of a cyclohexanehexol compound as defined in any one of claims 1 to 6, a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6)

A method for preventing or inhibiting amyloid oligomer and/or aggregate assembly, enhancing clearance of amyloid oligomers and/or aggregates, or slowing deposition of amyloid oligomers and/or aggregates in ocular cells of a subject comprising administering to the subject a medicament according to any one of claims 1 to 6.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6)

A method of reversing amyloid aggregate deposition and ocular cell degeneration after the onset of symptoms in a subject suffering from an ocular disease comprising administering to the subject a medicament according to any one of claims 1 to 6.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6)

Use of a cyclohexanehexol compound as defined in any one of claims 1 to 6 for treating an ocular disease.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A kit comprising at least one medicament according to any one of claims 1 to 9, a container, and instructions for treating an ocular disease.
